ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

EB-DUALNK

Its studies are mostly in Carcinoma, Ovarian Epithelial, led by Beijing Biotech.

Furthest: phase 2, since May 10, 20261 company-led study, 1 open or runningNext primary completion: Mar 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biotech11 open or runningphase 2since May 10, 2026May 10, 2026Mar 14, 2027phase 2 · NCT07589543

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2026First study: phase 2 study in Carcinoma, Ovarian EpithelialFirst studyNCT07589543 · 42 planned · China

Ahead

  1. Mar 14, 2027Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT07589543

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07589543Carcinoma, Ovarian Epithelial · China2RecruitingMar 14, 202742

How it is read

Names in the registry

  • “EB-DUALNK”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.